Mycovia Pharmaceuticals Expands Medical Affairs Team with Strategic New Hire
Susan McGaurn, Pharm.D. to lead Medical Affairs strategy as company advances late-stage research of oteseconazole (VT-1161), aiming to be the first FDA-approved treatment for recurrent vulvovaginal candidiasis
Durham, N.C. – April 27, 2020 – Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced the appointment of Susan McGaurn, Pharm.D. as Senior Director of Medical Affairs. In her role, Dr. McGaurn will spearhead strategic medical affairs efforts that will support the launch of oteseconazole (VT-1161), an oral antifungal product candidate for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC) that is currently in Phase 3 clinical development. RVVC is a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year and for which there is currently no FDA-approved treatment in the U.S.